News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
707,580 Results
Type
Article (42426)
Company Profile (296)
Press Release (664858)
Section
Business (207440)
Career Advice (2251)
Deals (35860)
Drug Delivery (98)
Drug Development (82052)
Employer Resources (176)
FDA (16249)
Job Trends (15100)
News (350323)
Policy (33003)
Tag
Academia (2618)
Alliances (50428)
Alzheimer's disease (1337)
Approvals (16231)
Artificial intelligence (217)
Bankruptcy (362)
Best Places to Work (11760)
Biotechnology (219)
Breast cancer (232)
Cancer (1792)
Cardiovascular disease (140)
Career advice (1876)
CAR-T (133)
Cell therapy (381)
Clinical research (66124)
Collaboration (708)
Compensation (379)
COVID-19 (2626)
C-suite (176)
Data (1701)
Diabetes (224)
Diagnostics (6386)
Earnings (86268)
Employer resources (151)
Events (114206)
Executive appointments (593)
FDA (17199)
Funding (628)
Gene therapy (265)
GLP-1 (676)
Government (4421)
Healthcare (19003)
Infectious disease (2746)
Interviews (376)
IPO (16620)
Job creations (3782)
Job search strategy (1594)
Layoffs (449)
Legal (8029)
Lung cancer (261)
Manufacturing (251)
Medical device (13339)
Medtech (13344)
Mergers & acquisitions (19630)
Metabolic disorders (584)
Neuroscience (1767)
NextGen: Class of 2025 (6631)
Non-profit (4536)
Northern California (2199)
Obesity (322)
Opinion (224)
Patents (179)
People (58140)
Phase I (20663)
Phase II (29165)
Phase III (21597)
Pipeline (787)
Postmarket research (2583)
Preclinical (8756)
Radiopharmaceuticals (244)
Rare diseases (337)
Real estate (6101)
Regulatory (22325)
Research institute (2388)
Resumes & cover letters (374)
Southern California (1881)
Startups (3701)
United States (19395)
Vaccines (634)
Weight loss (222)
Date
Today (80)
Last 7 days (789)
Last 30 days (2712)
Last 365 days (34839)
2025 (5407)
2024 (35741)
2023 (40537)
2022 (51754)
2021 (56257)
2020 (54672)
2019 (47212)
2018 (35603)
2017 (32778)
2016 (32324)
2015 (38253)
2014 (32030)
2013 (27105)
2012 (29396)
2011 (30039)
2010 (28091)
Location
Africa (782)
Arizona (216)
Asia (38755)
Australia (6487)
California (5014)
Canada (1750)
China (418)
Colorado (230)
Connecticut (239)
Europe (83949)
Florida (731)
Georgia (173)
Illinois (493)
Indiana (271)
Japan (128)
Maryland (764)
Massachusetts (3830)
Michigan (201)
Minnesota (345)
New Jersey (1425)
New York (1427)
North Carolina (880)
Northern California (2199)
Ohio (176)
Pennsylvania (1141)
South America (1167)
Southern California (1881)
Texas (732)
Utah (155)
Washington State (483)
707,580 Results for "turn biotechnologies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioCapital
HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases
HanAll Biopharma Co., Ltd. has signed an exclusive licensing agreement with Turn Biotechnologies, Inc., a pre-clinical stage biopharmaceutical company focused on cellular repair through epigenetic reprogramming.
May 28, 2024
·
7 min read
Biotech Bay
Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies
Turn Biotechnologies announced an exclusive global licensing agreement with pharmaceutical manufacturer HanAll Biopharma to develop groundbreaking medicines for the treatment of age-related eye and ear conditions.
May 28, 2024
·
4 min read
Biotech Bay
Turn Biotechnologies Discussed Emerging Therapies at Aesthetic Plastic Surgery Society Meeting
Turn Biotechnologies, a developer of novel mRNA medicines and enabling technologies, presented its breakthrough research and therapies to treat age-related diseases to members of the American Society for Aesthetic Plastic Surgery, known as The Aesthetic Society.
May 7, 2024
·
2 min read
Job Trends
Difficult Market Turns More Biopharma Leaders to Fractional Roles, Say Experts
For reasons including downsizing, avoiding retirement and a tight labor market, senior-level biopharma professionals are increasingly turning to fractional roles, according to two recruitment experts.
August 28, 2024
·
4 min read
·
Angela Gabriel
Deals
Pharmas Turn to Licensing Deals as Risky Science Rises
Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the biotech ecosystem? Experts weigh in.
January 8, 2025
·
3 min read
·
Annalee Armstrong
Biotech Bay
Turn Biotechnologies’ Expands eTurna™ Delivery Platform to Solve Delivery and Targeting Issues that Challenge Industry
Turn Biotechnologies announced the expansion of its eTurna™ delivery platform that is expected to overcome the greatest challenge to breakthrough therapies: The safe and efficient targeting of specific organs and cells.
January 3, 2024
·
2 min read
Editorial
You Can’t Buy Us: Biotechs Turn to Courts to Fight Off Potential Buyers
Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO underscore the cutthroat nature of biopharma dealmaking.
January 31, 2025
·
3 min read
·
Annalee Armstrong
Press Releases
Repair Biotechnologies and Genevant Sciences to Collaborate to Develop mRNA-LNP Therapy with First-in-Class Potential to Turn Back Atherosclerosis
September 27, 2024
·
2 min read
Biotech Beach
Turn Therapeutics Atopic Dermatitis Candidate Reduces Disease Severity by 57% In-Vivo
In a widely cited in-vivo model of atopic dermatitis, Turn Therapeutics’ atopic dermatitis candidate showed a dramatic reduction in disease severity versus placebo.
June 20, 2024
·
2 min read
Press Releases
CorMedix Inc. Added to Nasdaq Biotechnology Index
December 20, 2024
·
1 min read
1 of 70,758
Next
